AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...
March 25, 2025 – The FDA has approved a new treatment for adults with a life-threatening heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a rare but serious ...
The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...
This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...
which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today’s patients. Data were presented at the American College of ...
Yvonne Greenstreet, MBChB, CEO of Alnylam, expressed gratitude to all contributors to the clinical trials and emphasized the company’s commitment to further innovation for ATTR amyloidosis patients ..
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback